Previous 10 | Next 10 |
PART 1: Review of the week's Short Ideas - Column written by Jan Svenda Due to the Holiday Monday, we're publishing this week's Short Newsletter on Tuesday. This week, we begin by summarizing 3 Short Ideas, and drill down on a Vuzix Corp thesis. 1. Trupanion ( TRUP ) The ...
The trade war with China and the potential for a slowing U.S. economy have provided a unique investment opportunity for domestic small-cap companies. We have written about six unique investment opportunities that have great potential in 2019. These companies are both growth and value oriented ...
LEXINGTON, Mass., May 24, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that John McDonough, chief executive officer, and John Sprague, chief financial of...
T2 Biosystems ( TTOO ) is a little medical device company that is right on the cusp of breaking through to power your portfolio to top performance. It has FDA approval for its rollout panels that augur a new day of rapid reliable testing for life-threatening infections. The story supporting ...
Gainers: Netshoes (Cayman) Limited (NYSE: NETS ) +42% . MYnd Analytics (NASDAQ: MYND ) +16% . S&W Seed Company (NASDAQ: SANW ) +16% . Universal Corporation (NYSE: UVV ) +15% . L Brands (NYSE: LB ) +12% . Realm Therapeutics (NASDAQ: RLM ) +10% . Advanced Drainage Systems (NY...
Presentations at ECCMID and MAD-ID meetings demonstrate clinically actionable results and cost savings achieved with these panels Real-world experience reinforces multi-day time advantage demonstrated in the T2Bacteria 1,427-patient pivotal study, as compared to post-blood culture spe...
Obalon Therapeutics (NASDAQ: OBLN ) -47% on stock offering. More news on: Obalon Therapeutics, Inc., Ascent Capital Group, Inc., Weibo Corporation, Stocks on the move, Read more ...
Buyer Beware – T2 Biosystems is a disaster in progress. Its blood diagnostic machine is selling poorly because it is expensive and does not meet the needs of hospitals. White Diamond Research has documented the problems with this machine and the background of the company in two good art...
LEXINGTON, Mass., May 14, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, today announced that results from a pivotal trial were published online in the Annals of Inte...
On 3/5/19 we published a bearish report on T2 Biosystems ( TTOO ) with a 12-month target of $1.50. However, that target now looks conservative. We now believe TTOO could tumble to around $0.50 within a year, similar to how Viveve Medical ( VIVE ) has tumbled lower than our $0.90 price targe...
News, Short Squeeze, Breakout and More Instantly...
LEXINGTON, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the Nasdaq Stock Market LLC (ȁ...
2024-05-17 18:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
LEXINGTON, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has closed its previously announced private placement for the purchase and sale of an aggregat...